ADVERTISEMENTs
Trump’s pharma tariff spares generics, but India still feels heat
The announcement has sent ripples through the global pharmaceutical industry. By explicitly targeting branded and patented medicines, the measure spares generics — the lower-cost versions produced once patents expire.
-
Lalit K Jha (5WH) - Thu, 25, Sep 2025
- 23:39 EDT
- 23
Generic drugs have been exempted from the new tariff policy /
President Donald Trump announced on Sept. 25 a 100 percent tariff on branded and patented pharmaceutical imports, effective Oct. 1, 2025, unless companies establish manufacturing facilities in the United States. While generic medicines — India’s main export to America — are excluded on paper, the move has the potential to unsettle the USD20 billion industry that supplies nearly 40 per cent of US generics.
“Starting October 1, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump declared on his social media platform.
ALSO READ: Trump administration says India trade talks making progress
This post is for paying subscribers only
SUBSCRIBE NOWRelated
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login